CTLA4 and neoplasm: Control, anti‐CD8, and APG‐157 + anti‐CTLA‐4 + anti‐CD8 groups had tumor cell growth demonstrating loss of anti‐tumor activity when CD8+ T cells were depleted for the APG‐157 + anti‐CTLA‐4 treatment group (Figure 5B).